RxDoctor Payments Data

Roger Smith, MD

Internal Medicine · Wisner, LANPI 1023045671

Payments from drug & device makers

$1,472in general payments, 2019–2025

Across 30 payments — averaging $49.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$971
  • Bayer$168
  • Otsuka America Pharmaceutical, Inc.$47
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
  • AbbVie$43
  • Pfizer$32
  • plus $164 from 9 others

What the payments were for

  • Travel & lodging$97166%
  • Food & beverage$50134%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,472 in reported general payments places this provider in the 70th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$13,358
Medicare patients
831
Services billed
1,609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban490$211,637
EntrestoSacubitril/Valsartan166$86,937
RexultiBrexpiprazole89$82,223
JardianceEmpagliflozin114$67,533
FarxigaDapagliflozin Propanediol52$50,869
TrulicityDulaglutide51$50,759
JanuviaSitagliptin Phosphate146$47,509
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$43,261
MounjaroTirzepatide28$41,799
LinzessLinaclotide82$38,962
XareltoRivaroxaban88$34,454
OzempicSemaglutide35$32,221
TivicayDolutegravir Sodium12$26,954
NuedextaDextromethorphan Hbr/Quinidine29$21,362
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$20,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$211,637490 claims
Lilly USA, LLCTrulicity, Mounjaro$21$92,55879 claims
Otsuka America Pharmaceutical, Inc.Rexulti$47$82,22389 claims
AstraZenecaFarxiga, Brilinta$11$61,51465 claims
AbbVieLinzess, Namzaric$43$45,08993 claims
Avanir Pharmaceuticals, Inc.Nuedexta$16$21,36229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Wisner

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →